Bank of America
VRCA icon

Bank of America’s Verrica Pharmaceuticals VRCA Stock Holding History

Bank of America’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,343
Closed -$36.1K – 6893
2025
Q4 		$36.1K Buy
4,343
+4,271
+5,932% +$23.7K ﹤0.01% 5934
2025
Q3 		$310 Sell
72
-342
-83% -$2.06K ﹤0.01% 7663
2025
Q2 		$2.2K Sell
414
-2,121
-84% -$11.4K ﹤0.01% 7421
2025
Q1 		$11.2K Sell
2,535
-11,847
-82% -$76.6K ﹤0.01% 7093
2024
Q4 		$101K Buy
14,382
+11,168
+347% +$123K ﹤0.01% 6398
2024
Q3 		$46.6K Buy
3,214
+299
+10% +$13.5K ﹤0.01% 6565
2024
Q2 		$213K Buy
2,915
+218
+8% +$16.7K ﹤0.01% 5846
2024
Q1 		$160K Sell
2,697
-971
-26% -$53.6K ﹤0.01% 6004
2023
Q4 		$269K Buy
3,668
+83
+2% +$3.41K ﹤0.01% 5907
2023
Q3 		$139K Sell
3,585
-830
-19% -$42.2K ﹤0.01% 6101
2023
Q2 		$255K Buy
4,415
+671
+18% +$40.7K ﹤0.01% 5674
2023
Q1 		$243K Buy
3,744
+1,710
+84% +$103K ﹤0.01% 5826
2022
Q4 		$55.9K Buy
2,034
+63
+3% +$1.68K ﹤0.01% 6439
2022
Q3 		$57K Sell
1,971
-16,222
-89% -$556K ﹤0.01% 6618
2022
Q2 		$349K Buy
18,193
+12,604
+226% +$634K ﹤0.01% 5690
2022
Q1 		$454K Buy
5,589
+2,744
+96% +$226K ﹤0.01% 5906
2021
Q4 		$260K Buy
2,845
+1,839
+183% +$208K ﹤0.01% 6336
2021
Q3 		$125K Sell
1,006
-132
-12% -$14.8K ﹤0.01% 6596
2021
Q2 		$128K Sell
1,138
-1,054
-48% -$128K ﹤0.01% 6374
2021
Q1 		$332K Buy
2,192
+840
+62% +$116K ﹤0.01% 5681
2020
Q4 		$155K Sell
1,352
-138
-9% -$12.7K ﹤0.01% 5755
2020
Q3 		$115K Sell
1,490
-318
-18% -$26.1K ﹤0.01% 5619
2020
Q2 		$199K Sell
1,808
-3,044
-63% -$352K ﹤0.01% 5248
2020
Q1 		$531K Sell
4,852
-5,491
-53% -$723K ﹤0.01% 4468
2019
Q4 		$1.64M Sell
10,343
-787
-7% -$116K ﹤0.01% 4158
2019
Q3 		$1.64M Buy
11,130
+1,006
+10% +$112K ﹤0.01% 4203
2019
Q2 		$1.18M Buy
10,124
+1,601
+19% +$150K ﹤0.01% 4450
2019
Q1 		$921K Buy
8,523
+8,192
+2,475% +$945K ﹤0.01% 4578
2018
Q4 		$26K Buy
331
+258
+353% +$31.3K ﹤0.01% 6423
2018
Q3 		$12K Buy
73
+58
+387% +$9.91K ﹤0.01% 6635
2018
Q2 		$3K Buy
+15
New +$2.94K ﹤0.01% 6876

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's VRCA Position: Q1 2026 in Review

Bank of America sold out of Verrica Pharmaceuticals (VRCA) in Q1 2026, closing a stake of 4,343 shares — an estimated $36.1K sold.

Bank of America first reported a position in VRCA in Q2 2018 and held it in 31 quarters. The position peaked at $1.64M in Q4 2019. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • Bank of America reported no remaining Verrica Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 4,343 Verrica Pharmaceuticals shares in Q1 2026, an estimated $36.1K.
  • Bank of America first reported a position in Verrica Pharmaceuticals in Q2 2018 and held it in 31 quarters.
  • Bank of America's Verrica Pharmaceuticals position peaked at $1.64M in Q4 2019.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.